Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telisotuzumab adizutecan
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Telisotuzumab adizutecan is an antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors. It consists of a c-Met–targeting monoclonal antibody (telisotuzumab) conjugated to a topoisomerase 1 inhibitor payload (adizutecan). The drug is designed to selectively deliver cytotoxic chemotherapy to tumor cells overexpressing the c-Met protein, which is implicated in tumor growth and progression. Telisotuzumab adizutecan has shown antitumor activity in multiple cancer types, including colorectal cancer, non-small cell lung cancer, and gastroesophageal adenocarcinoma. Its mechanism involves binding to c-Met on tumor cells, internalization of the ADC, and intracellular release of the topoisomerase inhibitor payload leading to DNA damage and cell death.
- Other names
- telisotuzumab adizutecan
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on telisotuzumab adizutecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telisotuzumab adizutecan.